Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma

Human Pathology

Volumn 51, Issue , 2016, Pages 9-15

  Andrici, Juliana ^a,b   Jung, Jason ^a   Sheen, Amy ^a,b   D'Urso, Lisa ^a,b,c   Sioson, Loretta ^a,b   Pickett, Justine ^a,b   Parkhill, Thomas R ^a   Verdonk, Brandon ^a   Wardell, Kathryn L ^a   Singh, Arjun ^a   Clarkson, Adele ^a,c   Watson, Nicole ^a   Toon, Christopher W ^a,b,d   Gill, Anthony J ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d Histopath Pathology   (Australia)

Author keywords

BAP1; BRCA1 associated protein 1; Serous adenocarcinoma

Indexed keywords

BAP1 PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ABDOMINAL MESOTHELIOMA; ADULT; AGED; ARTICLE; CANCER MORPHOLOGY; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFERENTIAL DISPLAY; FEMALE; FEMALE GENITAL TRACT CANCER; GYNECOLOGIC SEROUS ADENOCARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PERITONEAL SEROUS ADENOCARCINOMA; PERITONEUM CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY; VERY ELDERLY; ABDOMINAL NEOPLASMS; BIOSYNTHESIS; CYSTADENOCARCINOMA, SEROUS; MESOTHELIOMA; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; YOUNG ADULT;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 84978971811     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.12.012     Document Type: Article

References (24)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
2. [2] Torre, L.A., Bray, F., Siegel, R.L., et al. Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
3. [3] Kannerstein, M., Churg, J., McCaughey, W., et al. Papillary tumors of the peritoneum in women: mesothelioma or papillary carcinoma. Am J Obstet Gynecol 127 (1977), 306–314.
4. [4] Laury, A.R., Hornick, J.L., Perets, R., et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 34 (2010), 627–635.
5. [5] Barnetson, R.J., Burnett, R.A., Downie, I., et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 125 (2006), 67–76.
6. [6] Chu, A.Y., Litzky, L.A., Pasha, T.L., et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 18 (2005), 105–110.
7. [7] Comin, C.E., Dini, S., Novelli, L., et al. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type. Am J Surg Pathol 30 (2006), 463–469.
8. [8] Drapkin, R., von Horsten, H.H., Lin, Y., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65 (2005), 2162–2169.
9. [9] Frierson, H.F., Moskaluk, C.A., Powell, S.M., et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. HUM PATHOL 34 (2003), 605–609.
10. [10] Galgano, M.T., Hampton, G.M., Frierson, H.F., Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19 (2006), 847–853.
11. [11] Nakatsuka, S., Oji, Y., Horiuchi, T., et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19 (2006), 804–814.
12. [12] Ordóñez, N.G., Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 22 (1998), 1203–1214.
13. [13] Attanoos, R.L., Webb, R., Dojcinov, S.D., et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 40 (2002), 237–244.
14. [14] Murali, R., Wiesner, T., Scolyer, R.A., Tumours associated with BAP1 mutations. Pathology 45 (2013), 116–126.
15. [15] Ventii, K.H., Devi, N.S., Friedrich, K.L., et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 68 (2008), 6953–6962.
16. [16] Wadt, K.A., Aoude, L.G., Johansson, P., et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet 88 (2015), 267–272.
17. [17] Peña-Llopis, S., Vega-Rubín-de-Celis, S., Liao, A., et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 44 (2012), 751–759.
18. [18] Nasu, M., Emi, M., Pastorino, S., et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 10 (2015), 565–576.
19. [19] Farzin, M., Toon, C.W., Clarkson, A., et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 47 (2015), 302–307.
20. [20] Hwang, H.C., Sheffield, B.S., Rodriguez, S., et al. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol 40 (2016), 120–126.
21. [21] Andrici, J., Sheen, A., Sioson, L., et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol 28 (2015), 1360–1368.
22. [22] McGregor, S.M., Dunning, R., Hyjek, E., et al. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. HUM PATHOL 46 (2015), 1670–1678.
23. [23] Alakus, H., Yost, S., Woo, B., et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med, 13, 2015, 122.
24. [24] Edge, S.B., Byrd, D.R., Compton, C.C., et al. AJCC Cancer Staging Manual. 7th Edition. 2009, Springer, Chicago.